Evolve BioSystems, UC Davis baby-probiotic spinout, is going global with new $40M financing

Photo of Evolve BioSystems CEO Tim Brown courtesy of Evolve.
  • Series C lead investors: Gates Foundation, Li Ka Shing Foundation venture arm
  • First outside investment: $1 million seed round in ’14
  • Evolve looks to penetrate Asia market, develop microbiome diagnostic test
Evolve BioSystems is gearing up to take its infant probiotic global and create new products that fight malnutrition, having scored a $40 million Series C financing led by the Bill and Melinda Gates Foundation and Horizon Ventures, Li Ka Shing ...

PE Hub Healthcare Wire delivers private equity and M&A healthcare deal activity, fundraising news, people moves, regulatory updates and much more every Thursday. Subscribe now! It’s FREE.

This content is available for Buyouts subscribers only. Request a free trial to get access for a limited period

If you already have an active Buyouts subscription, please sign in to view this article.

Digital Edition

To read a digital copy of our latest magazine

click here

PE News Briefs